Join our dedicated team

Specialized team of scientists

BSL 2 & BSL 3 Facilities

Large Scale Diagnostic Services

Specialized Consultancy Services

NEWS

ViroSpot MN assay, a novel tool for antigenic characterization of influenza viruses and serology.
The ViroSpot assay platform is currently available for influenza virus and RSV, and under development for multiple other viral targets.

Virology Contract Research Laboratory

Specialized team of scientists

BSL 2 & BSL 3 Facilities

Large Scale Diagnostic Services

Specialized Consultancy Services

NEWS

ViroSpot MN assay, a novel tool for antigenic characterization of influenza viruses and serology.
The ViroSpot assay platform is currently available for influenza virus and RSV, and under development for multiple other viral targets.

ViroSpot MN assay, a novel tool for antigenic characterization of influenza viruses and serology

Selecting vaccine strains that match circulating influenza viruses antigenically remains an annual challenge. Vaccine mismatch [e.g., for recent A(H3N2) viruses] has contributed to reduced vaccine effectiveness. Reduced vaccine effectiveness not only may affect public health, but also causes economic losses due to absenteeism from work. Vaccine mismatches also fuel the ongoing debate about the effectiveness of the influenza vaccine.

Headquartered in Rotterdam, The Netherlands

Headquartered in Rotterdam, The Netherlands

Viroclinics Biosciences operates at a global level and is the preferred virology testing laboratory for several of the top 10 biopharmaceutical companies. Our mission is to improve human and animal health by serving the biopharmaceutical community with state-of-the-art diagnostics, custom-made models in (pre)clinical drug testing and expert advice on development of antivirals and vaccines.

Headquartered in Rotterdam, The Netherlands

Headquartered in Rotterdam, The Netherlands

Viroclinics Biosciences operates at a global level and is the preferred virology testing laboratory for several of the top 10 biopharmaceutical companies. Our mission is to improve human and animal health by serving the biopharmaceutical community with state-of-the-art diagnostics, custom-made models in (pre)clinical drug testing and expert advice on development of antivirals and vaccines.

Systeembeheerder (0.6 FTE)

Viroclinics Biosciences is een leider in de uiterst dynamische en sterk groeiende markt van diagnostische service voor klinische en preklinische studies van farmaceutische bedrijven en vaccin producenten. Wij verzorgen als service organisatie voor onze opdrachtgevers...

SERVICIO DE PRUEBAS DE DIAGNOSTICO

El servicio de pruebas de diagnóstico clínico apoya y acelera la entrada al mercado de nuevos fármacos, vacunas y antivirales, así como ayudan en los programas de vigilancia previa y posterior a la comercialización. Los servicios están personalizados siendo adaptados a las necesidades específicas, lo que permite una máxima flexibilidad en el análisis día a día y un alto rendimiento.

SERVICIOS OPERATIVOS DE ANÁLISIS CLÍNICO

El departamento de Operaciones de Análisis Clínico es la última incorporación a Viroclinics. Proporcionando un mejor soporte logístico para el sector farmacéutico, biotécnico e industrias de dispositivos médicos, así como también asigna a Viroclinics la oportunidad de monitorear la calidad, desde el momento que la muestra es recogida hasta la obtención de los resultados.

SERVICIOS PRE-CLINICOS

Los servicios preclínicos incluyen pruebas de eficacia, seguridad, PK e inmuno-toxicología de fármacos, anticuerpos, vacunas y antivirales enfocadas en enfermedades infecciosas virales. Nuestras instalaciones BSL-2 y BSL-3 permiten complejos experimentos con virus altamente patógenos.

DEPARTAMENTO DE GARANTÍA DE CALIDAD  

Viroclinics ha adoptado un estándar de alta calidad en todas las operaciones, procedimientos de pruebas y presentación de informes. El sistema de gestión de calidad se basa en NEN-EN-ISO 15189, ampliado con elementos de la GCP y GLP, para cumplir con los requisitos reglamentarios y facilitar las presentaciones regulatorias.

DESCUBRIMIENTO DE VIRUS

Viroclinics participa en los programas de vigilancia a nivel mundial para custodiar y caracterizar las amenazas de virus novedosos para la salud humana y animal (EMPERIE; UE FP-7).

Clinical and technical validation studies for diagnostic companies

• Detection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture.
• Performance evaluation of the new Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 for quantification of human immunodeficiency virus type 1 RNA.
• Comparison of the Abbott Realtime HIV-1 and HCV viral load assays with commercial competitor assays.
• Evaluation of the analytical performance of the new Abbott RealTime RT-PCRs for the quantitative detection of HCV and HIV-1 RNA.
• Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA.

Clinical studies and cases

Influenza viruses | Dengue viruses:
• The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.
• Fatal Dengue in Patients with Sickle Cell Disease of Sickle Cell Anemia in Curacao: two case reports.
• Validation of self-swab for virologic confirmation of influenza virus infections in a community setting.
• Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus.
• Fatal oseltamivir-resistant influenza virus infection.
• Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome.

Ohter Viruses:
• Deep sequencing does not reveal additional transmitted mutations in patients diagnosed with HIV-1 variants with single nucleoside reverse transcriptase inhibitor resistance mutations.
• Therapy failure resulting from superinfection by a drug resistant HIV variant.
• Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-a/ribavirin treatment for chronic hepatitis C.
• Fatal human rabies due to Duvenhage virus from a bat in Kenya: failure of treatment with coma-induction, ketamine, and antiviral drugs.
• Norovirus in a Dutch tertiary care hospital (2002-2007): frequent nosocomial transmission and dominance of GIIb strains in young children.
• On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks.
• Complete clinical and virological remission of refractory HIV-related Kaposi’s sarcoma with pegylated interferon alpha.
• Antiretroviral therapy in patients with dual infection with human immunodeficiency virus types 1 and 2.

Virus discovery, new previously unidentified viruses in man and animals.

Indentifying emerging pathogens | Deep sequencing:
• Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study.
• Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.
• Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.
• Novel hepatitis E virus in ferrets, the Netherlands.
• Picobirnaviruses in the Human Respiratory Tract.
• High prevalence of anelloviruses in vitreous fluid of children with seasonal hyperacute panuveitis.
• Metagenomic analysis of the viral flora of pine marten and European badger feces.
• Calicivirus from novel recovirus genogroup in human diarrhea, bangladesh.
• Genogroup I and II picobirnaviruses in respiratory tracts of pigs.
• Enteric coronavirus in ferrets, The Netherlands.
• Identification and characterization of deer astroviruses.
• Human picobirnaviruses identified by molecular screening of diarrhea samples.
• Human astrovirus infection in a patient with new-onset celiac disease.
• A previously undescribed coronavirus associated with respiratory disease in humans.

Animal model development: other species / other viruses, etc.

Ferrets | Rabbits | Cats | Non-human primates:
• Low pathogenic avian influenza A(H7N9) virus causes high mortality in ferrets upon intratracheal challenge: A model to study intervention strategies.
• Animal models.
• Distinct SARS-Coronavirus Induced Acute Lung Injury Pathways in Two Different Non-Human Primate Species.
• Experimental pandemic (H1N1) 2009 virus infection of cats.
• Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
• Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine.

Animal model development: novel approaches

Immunocompromised ferret model | In vivo imaging | Rapid development of animal models for emerging viruses:
• Transmission of Human Respiratory Syncytial Virus in the Immunocompromised Ferret Model
• Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets.
• Modification of the ferret model for pneumonia from seasonal human influenza a virus infection.
• Pulmonary pathology of pandemic influenza A/H1N1 virus (2009)-infected ferrets upon longitudinal evaluation by computed tomography.
• Severity of pneumonia due to new H1N1 influenza virus in ferrets is intermediate between that due to seasonal H1N1 virus and highly pathogenic avian influenza H5N1 virus.
• Experimental pandemic (H1N1) 2009 virus infection of cats.

Vaccine immunogenicity- and efficacy testing in ferrets  

Humoral immune responses (ELISA, Virus Neutralization, Plaque Reduction, Haemagglutination Inhibition, etc. ) | Cell-mediated immune responses | Prime-boost strategies | Production of hyper immune serum | Longevity of protection | Dose-finding, Dose-optimization | Clinical scoring:
• Intranasal H5N1 Vaccines, Adjuvanted with Chitosan Derivatives, Protect Ferrets against Highly Pathogenic
• Influenza Intranasal and Intratracheal Challenge.
• Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets.
• Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets.
• Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets.
• A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets.
• Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
• Seasonal influenza vaccine provides priming for A/H1N1 immunization.
• Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.

↓